- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05503134
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML (KARMA)
Killer Cells Against Relapsed/Refractory Myeloid Acute Leukemia (KARMA): A Clinical Trial Evaluating the Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Treatment of Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 18-24.99 with relapsed or refractory acute myeloid leukemia.
PRIMARY OBJECTIVE:
I. To determine the safety and recommended phase II dose of adoptive NK cell therapy using UD-NK cells in patients with relapsed/refractory AML
SECONDARY OBJECTIVES:
I. To estimate the efficacy of UD- NK cells with FLA chemotherapy in patients with relapsed/refractory AML
EXPLORATORY OBJECTIVES:
I. To determine the immunophenotype and function of UD-NK cells
II. To characterize in vivo expansion of UD-NK cells
III. To determine the persistence of UD-NK cells
Six doses of universal donor mbIL-21 expanded NK cells (UD-NK) given thrice weekly for two weeks. Days may vary and NK cells can be given from days 0 to 21. Patients may receive up to 2 cycles of fludarabine/cytarabine (FLA) + NK cells (up to 12 NK cell infusions) if they do not achieve CR after cycle 1 or if necessary to bridge to transplant.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The treatment plan consists of Fludarabine/Cytarabine chemotherapy followed by six doses of universal donor mbIL-21 expanded NK cells (UD-NK) given thrice weekly for two weeks. Days may vary and NK cells can be given from days 0 to 21. Patients may receive up to 2 cycles of fludarabine/cytarabine (FLA) + NK cells (up to 12 NK cell infusions) if they do not achieve CR after cycle 1 or if necessary to bridge to transplant.
In this study the first NK cell infusion is referred as day zero (D0), treatment plan activities prior or after D0 are denominated as day minus (D-) or day plus (D+).
FLA will be give as follows: Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2000 mg/ m2/day (days -6 to day -2)
Six doses of UD-NK cells will be given thrice weekly for two weeks beginning day 0. NK cell administration schedule may vary and doses may be given from day 0 to 21. A minimum of 2 days between NK cell doses is required. Patients must meet eligibility criteria for NK cell infusion as described in the protocol.
Patients will be eligible to receive a second cycle of chemotherapy for the following reasons:
- <CR after cycle 1
- Additional cycle is needed to bridge the patient to HSCT
Criteria to begin Cycle 2:
- ≥28 days since the first NK Cell infusion
- ≥2 days since the last NK Cell infusion in cycle 1
- Bone marrow evaluation after cycle 1 complete
- It is suggested but not required for ANC > 500/uL AND platelets >50,000/uL prior to beginning cycle 2
- Prior treatment related toxicities must have resolved to ≤ Grade 2
NK Cell Dose Levels:
- Dose level 1: 1.00x10^7 NK cell/kg (±20%) each dose for 6 doses per cycle
- Dose level 2: 3.00x10^7 NK cell/kg (±20%) each dose for 6 doses per cycle
- Dose level 3: 1.00x10^8 NK cell/kg (±20%) each dose for 6 doses per cycle
The NK dose will be calculated based on actual body weight. Dose escalation will proceed according to the study design outlined in Section 9.1 to determine the MTD. Once a patient is enrolled at a dose level, the dose will remain at the enrolled dose level for all subsequent NK cell infusions.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Melinda C Triplet
- Phone Number: 6147226039
- Email: Melinda.Triplet@nationwidechildrens.org
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
Contact:
- Melinda Triplet
- Phone Number: 614-722-6039
- Email: melinda.triplet@nationwidechildrens.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with relapsed or primary refractory AML, including:
- Patients with relapsed AML after allogeneic stem cell transplantation
- Isolated CNS or extramedullary disease
- Primary refractory AML defined as failure to achieve a complete response (<5% BM blasts) after 2 cycles of induction chemotherapy
- Patient age 18-24.99 years old
Negative serum test to rule out pregnancy within 2 weeks prior to enrollment in females of childbearing potential
- Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator for 6 months after the last dose of chemotherapy and/or NK cell infusion
- Negative serology for human immunodeficiency virus (HIV)
- Both males and females and members of all races and ethnic groups are eligible
Organ function requirements:
- Renal function: Creatinine ≤ 2 mg/dl OR creatinine clearance > 60 ml/min/1.73m2.
- Liver function: Total bilirubin ≤ 2 mg/dl (unless Gilbert's syndrome), AST ≤ 150, and ALT ≤108 (unless related to leukemic involvement)
- Cardiac function: left ventricular ejection fraction ≥ 40% or shortening fraction ≥20%. May be eligible after cardiology clearance if qualitatively normal function or repeat measures are normal.
- CNS: Patients with seizure disorder may be eligible if seizures well controlled
- Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, stem cell transplant or radiotherapy prior to entering this study
- All prior treatment related toxicities must have resolved to ≤ Grade 2 prior to enrollment
- All patients and/or their legal guardians must be able to understand and willing to sign a written informed consent document
Exclusion Criteria:
AML directed therapies in the 2 weeks prior to beginning treatment on this protocol (except for hydroxyurea)
- Note: There is no waiting period required for patients having received intrathecal cytarabine, methotrexate and/or hydrocortisone
Patients on immunosuppressive therapy
- Patients must be off of all systemic immunosuppressive therapy for at least 2 weeks prior to enrollment with no evidence of recurrent GVHD
- Patients with a history of donor lymphocyte infusion within the last 30 days are not eligible for this study
- Allogeneic SCT < 3 months prior to study enrollment
- Any comorbidities that in the opinion of the investigator will preclude receiving study therapy
- Performance status: Karnofsky or Lansky Performance Scale (PS) < 50
Uncontrolled infection, defined as an infection which has not resolved spontaneously or does not show evidence of significant resolution after initiating appropriate therapy
- Asymptomatic viremia such as CMV, HPV, BK virus, HCV, etc. is NOT considered as an exclusion criterion
- Uncontrolled arrhythmias or uncontrolled symptomatic cardiac disease
- History of autoimmune disease
- Active GVHD at the time of enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2000 mg/ m2/day (days -6 to day -2) Six doses of universal donor IL-21 expanded NK cells (UD-NK) given thrice weekly for two weeks starting on day 0. Days may vary and NK cells can be given from days 0 to 21. Patients may receive up to 2 cycles of fludarabine/cytarabine (FLA) + NK cells (up to 12 NK cell infusions) if they do not achieve CR after cycle 1 or if necessary to bridge to transplant. |
Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of adverse events
Time Frame: Up to 56 days after the first NK cell infusion
|
Up to 56 days after the first NK cell infusion
|
Rate of dose limiting toxicities
Time Frame: Up to 56 days after the first NK cell infusion
|
Up to 56 days after the first NK cell infusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Minimal Residual Disease (MRD) negative response rate by flow cytometry
Time Frame: At the end of Cycle 1 and Cycle 2 (each cycle is 28 days)
|
At the end of Cycle 1 and Cycle 2 (each cycle is 28 days)
|
CR rate after first cycle
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
Relapse free survival and overall survival
Time Frame: 1 year
|
1 year
|
Median time to neutrophil and platelet count recovery
Time Frame: 1 year
|
1 year
|
Median duration of remission for patients who do not go onto transplant
Time Frame: 1 year
|
1 year
|
Incidence of infectious complications
Time Frame: 1 year
|
1 year
|
Percentage of patients receiving this regimen who are rendered transplant-eligible
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunophenotype of UD-NK cells
Time Frame: Weekly samples from day 0 to day +28 after the first NK cell infusion for each cycle (each cycle is 28 days)
|
Immunophenotyping by flow cytometry and CyTOF.
|
Weekly samples from day 0 to day +28 after the first NK cell infusion for each cycle (each cycle is 28 days)
|
Function of UD-NK Cells
Time Frame: Day 0 of the first cycle
|
Cytokine secretion and cytotoxicity of UD-NK cells cultured with patient leukemia samples
|
Day 0 of the first cycle
|
Expansion/persistence of UD-NK cells after infusion
Time Frame: Weekly samples from day 0 to day +28 after the first NK cell infusion for each cycle (each cycle is 28 days)
|
Peripheral blood will be obtained before therapy, during the NK cell treatment period, and after NK cell treatment to evaluate for UD-NK cell expansion and persistence.
UD-NK cells will be identified by chimerism assay.
Chimerism may be determined by flow cytometry using haplotype-specific antibodies, short tandem repeat polymorphisms, or when there is a sex-mismatch between the donor and the recipient, assays based on determining the frequency of sex-chromosomes may be used.
|
Weekly samples from day 0 to day +28 after the first NK cell infusion for each cycle (each cycle is 28 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Margaret Lamb, MD, Nationwide Children's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KARMA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
Clinical Trials on Universal Donor Natural Killer Cells
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedAcute Lymphoblastic Leukemia | Acute Myelogenous LeukemiaKorea, Republic of
-
Asan Medical CenterKorea Research Institute of Bioscience & BiotechnologyCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative NeoplasmsKorea, Republic of
-
University of NebraskaWithdrawn
-
Hospital de Clinicas de Porto AlegreUnknown
-
Zhejiang UniversityRecruiting
-
Sabine Mueller, MD, PhDWashington University School of Medicine; Nationwide Children's Hospital; Rally...Not yet recruitingPediatric Brain Tumor | Recurrent Pediatric Brain Tumor | Pediatric Supratentorial NeoplasmUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
-
Michael Pulsipher, MDSeattle Children's Hospital; Nationwide Children's HospitalEnrolling by invitation
-
Hospital Infantil Universitario Niño Jesús, Madrid...TerminatedRelapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and LymphomaSpain
-
Brenda Cooper, MDCompletedSoft Tissue Sarcoma | Acute Myeloid Leukemia | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Plasma Cell Myeloma | Rhabdomyosarcoma | Colon Carcinoma | Adenocarcinoma of Rectum | Myeloproliferative Syndromes and other conditionsUnited States